Understand the study
Tirzepatide SURMOUNT-1: Reading the Weight-Loss Numbers
What 2,539 participants, three study groups and a placebo comparison tell us.
Start with the question
SURMOUNT-1 tested whether tirzepatide changed body weight in adults with obesity or overweight and a related complication. Diabetes was excluded. This matters because a result from one population does not automatically describe another. Tirzepatide targets GIP and GLP-1 receptors; the trial tested outcomes rather than relying on that mechanism alone.
Why include a placebo group?
The 2,539 participants were randomly assigned to three tirzepatide groups or placebo and followed for 72 weeks. Random assignment helps make groups comparable. A placebo group also shows what happens in the study setting without the active compound. Simply comparing a person with their own starting weight cannot provide the same information. [1]
- 01Tirzepatide groups
- 02Placebo group
- 03Compare at week 72
What were the reported changes?
Average weight changes were −15.0%, −19.5% and −20.9% in the 5, 10 and 15 mg groups, versus −3.1% with placebo. The percentages describe change from starting weight. Trial group labels are reported here only to explain the paper, not to recommend a regimen. [1]
How big is the difference?
Subtracting the two percentages gives 17.8 percentage points. This is a difference between group averages. For a hypothetical 100 kg starting weight, a 20.9% reduction would mean 20.9 kg. The example explains the unit; actual participants had different starting weights and outcomes. An average also cannot show who stopped treatment or had adverse events.
Do not skip tolerability
Digestive events were common. Discontinuation because of adverse events was 4.3%, 7.1% and 6.2% in the three tirzepatide groups, compared with 2.6% for placebo. The study does not directly rank tirzepatide against retatrutide. Differences between separate trials can reflect their populations, timing and analysis. [1]
Find the related product
The product page identifies NHD’s tirzepatide research material and inquiry options. It is not the finished clinical product used in SURMOUNT-1. Tell the team the laboratory question, required variant, quantity and records needed so that the material request can be checked separately from the publication.
Explore the research topic
Related research products
Tirzepatide
Weight and metabolism research
View product
Retatrutide
Weight and metabolism research
View product
Survodutide
Weight and metabolism research
View productImages illustrate the catalog. Related products are further reading, not claims of equal effects or interchangeability.
Original research and reading notes
Study amounts and preparations identify experimental conditions, not recommended use. AI-assisted research explanation; sources checked 11 October 2026. NHD catalog materials are for research, development and manufacturing, not human or veterinary use.